Accord Healthcare Inc. beat competitor Knoa Pharmaceuticals LLC’s bid to overturn the invalidation of a patent protecting OxyContin.
The lower court didn’t err in determining that claim 18 of US Patent No. 11,304,908 was invalid due to obviousness, the US Court of Appeals for the Federal Circuit said Monday. An expert’s testimony concerning teachings on an abuse-proofed oxycodone formulation was “credible and convincing,” Judge Richard Seeborg, sitting by designation, said for the court.
The lower court determined that a person of ordinary skill in the art would have been motivated to modify prior teachings by curing the tablets in a ...